Investigator Sponsored Phase I/II study of AXL1717 in Patients with Brain Tumors
News Apr 25, 2013
Axelar AB has announced that an investigator sponsored Phase I/II study with AXL1717 in patients with malignant astrocytomas, a type of brain tumor, has commenced in the United States.
The study is conducted at the Rush University Medical Center in Chicago in patients with relapsed or progressive malignant astrocytomas (glioblastoma and anaplastic astrocytoma), with AXL1717 - an oral small-molecule insulin-like Growth Factor 1 (IGF-1) receptor inhibitor - as the investigational drug.
Astrocytoma represents about half of all primary tumors of the brain and spinal cord. The most common malignant brain tumors in adults, glioblastomas, make up about two-thirds of all astrocytomas.
This study is also supported by Voices Against Brain Cancer and Gateway for Cancer Research.
More detailed information about the study can be found on www.clinicaltrials.gov (Identifier: NCT01721577).
Dr. Carl Harald Janson, CEO, Axelar AB “We are very pleased to support this investigator sponsored study in astrocytomas with supply of study drug. Preclinical data supports treatment with AXL1717 in patients with astrocytomas and we now look forward to follow this important clinical study, since treatment for astrocytomas remains very challenging and new advances are necessary to improve clinical outcome.”
Genomics Researchers Showcase their Applications of Droplet Digital PCR at ASHG 2017 Annual MeetingNews
The sensitivity and reliability of Droplet Digital PCR will be showcased in over a dozen presentations at the American Society of Human Genetics (ASHG) 2017 Annual Meeting.READ MORE
DataArt Joins Biotechnology Association BIO DeutschlandNews
Global technology consultancy DataArt announced today that it has joined BIO Deutschland, Germany's biotechnology industry association.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE
Comments | 0 ADD COMMENT
Annual Conference on Antimicrobials and Drug Resistance
Sep 24 - Sep 25, 2018
1st Alpine Winter Conference on Medicinal and Synthetic Chemistry
Jan 28 - Feb 01, 2018